Remarkable Short-Term Regression of a Posterior Mediastinum Metastasis From Primary Intraosseous Carcinoma Treated With Nivolumab: A Case Report

El-Naggar, 2017 Cariati, 2017, Primary intraosseous odontogenic squamous cell carcinoma of the mandible, J Oral Maxillofac Pathol, 21, 182, 10.4103/0973-029X.203777 Wenguang, 2016, Prognostic factors of primary intraosseous squamous cell carcinoma (PIOSCC): A retrospective review, PLoS One, 11, e0153646, 10.1371/journal.pone.0153646 McDermott, 2013, PD-1 as a potential target in cancer therapy, Cancer Med, 2, 662, 10.1002/cam4.106 Topalian, 2015, Immune checkpoint blockade: A common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001 Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates, J Clin Oncol, 28, 3167, 10.1200/JCO.2009.26.7609 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Wang, 2014, In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates, Cancer Immunol Res, 2, 846, 10.1158/2326-6066.CIR-14-0040 Ferris, 2017, Nivolumab for squamous-cell cancer of head and neck, N Engl J Med, 376, 596 Kies, 2010, Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial, J Clin Oncol, 28, 8, 10.1200/JCO.2009.23.0425 Naruse, 2016, Clinicopathological study of primary intraosseous squamous cell carcinoma of the jaw and a review of the literature, J Oral Maxillofac Surg, 74, 2420, 10.1016/j.joms.2016.05.006 Bodner, 2011, Primary intraosseous squamous cell carcinoma arising in an odontogenic cyst: A clinicopathologic analysis of 116 reported cases, J Oral Pathol Med, 40, 733, 10.1111/j.1600-0714.2011.01058.x Huang, 2009, Primary intraosseous squamous cell carcinoma of the jaws. Clinicopathologic presentation and prognostic factors, Arch Pathol Lab Med, 133, 1834, 10.5858/133.11.1834 Thomas, 2001, Primary intraosseous carcinoma of the jaw: Pooled analysis of world literature and report of two new cases, Int J Oral Maxillofac Surg, 30, 349, 10.1054/ijom.2001.0069 Woolgar, 2013, Intraosseous carcinoma of the jaws: A clinicopathologic review. Part III: Primary intraosseous squamous cell carcinoma, Head Neck, 35, 906, 10.1002/hed.22922 Hirakawa, 2017, Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma, Jpn J Clin Oncol, 47, 1038, 10.1093/jjco/hyx097 Vishak, 2015, Neoadjuvant chemotherapy in oral cancers: Selecting the right patients, Indian J Med Paediatr Oncol, 36, 148, 10.4103/0971-5851.166716 Zhong, 2013, Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma, J Clin Oncol, 31, 744, 10.1200/JCO.2012.43.8820 Maruse, 2018, Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma, Int J Oral Maxillofac Surg, 47, 836, 10.1016/j.ijom.2018.01.004 Schvartsman, 2017, Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer, Lung Cancer, 112, 90, 10.1016/j.lungcan.2017.07.034 Harrington, 2017, Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial, Lancet Oncol, 18, 1104, 10.1016/S1470-2045(17)30421-7 Kiyota, 2017, A randomized, open-label, phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141, Oral Oncol, 73, 138, 10.1016/j.oraloncology.2017.07.023